News | Chronic Total Occlusion (CTO) | November 02, 2017

Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI

Boston Scientific catheter yields similar crossing time, success and complication rates compared to wire escalation

Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI

November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure. Researchers randomized 246 patients undergoing coronary CTO intervention to upfront use of the CrossBoss catheter (N=122) or wire escalation (N=124) at 11 U.S. centers. Overall technical and procedural success rates were high and similar between the two groups. The primary efficacy endpoint, crossing time, was similar: 56 (interquartile range: 33, 93) minutes in the CrossBoss and 66 (36, 105) minutes in the wire escalation group (P=0.323), as was the incidence of procedural major adverse cardiovascular events (3.28 percent vs. 4.03 percent, P= 1.000). In the CrossBoss-first strategy, the first crossing technique was more likely to be antegrade dissection/re-entry (77 percent), compared with the wire escalation strategy, which was successful as the initial strategy 98 percent of the time among patients randomized to that study arm.

Trial results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 annual conference, Oct. 29-Nov. 2 in Denver.

“The CrossBoss First trial is the first randomized-controlled trial designed to compare two commonly utilized crossing techniques as the initial CTO crossing strategy,” said Emmanouil S. Brilakis, M.D., of the Minneapolis Heart Institute. “Compared with a primary wire escalation strategy, upfront use of the CrossBoss catheter for crossing CTOs was associated with similar crossing time, similar success and complication rates, and similar equipment utilization and cost. In a post hoc analysis upfront use of the CrossBoss catheter was associated with shorter crossing time in patient with in-stent CTOs. Use of antegrade dissection/re-entry was the final successful strategy in 22 percent of the wire escalation group patients.”

The CrossBoss First study was funded by Boston Scientific. Brilakis reported consulting/speaker honoraria from Abbott Vascular, Amgen, Asahi, CSI, Elsevier, GE Healthcare and Medicure. He also disclosed research support from Boston Scientific and Osprey, and that his spouse is an employee of Medtronic.

Read about other TCT 2017 late-breaking clinical trial presentations.

For more information: www.tctconference.com

Related CTO Content

VIDEO: Treating Chronic Total Occlusions

VIDEO: New Technology to Treat Chronic Total Occlusions (CTOs)

When to Consider Revascularization of Coronary Chronic Total Occlusions


Related Content

News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

Home March 01, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
Subscribe Now